A number of leading pharmaceuticals executives have said that recent US tax reforms will create a more conducive environment for patent transactions. Corroborating forecasts made by leading industry analysts suggest that 2018 will see a significant surge in this kind of deal-making in the life sciences sector.

Want to read more?

Register to access two of our subscriber-only articles per month

Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts

Already registered? Log in

What our customers are saying

IAM is the only publication that places a business focus on intellectual property. Readers are given real insight into, and guidance on, managing intellectual property as a true business asset.

Marc Kaufman
Partner
Reed Smith LLP

Benefits

Subscribe to receive access to the full range of premium business intelligence, insights and analysis, as well as our IP directories, guides and daily news.

Why subscribe?